ArticlePharmaceutical research2026
Transdermal Ionic Liquid Gel of Erlotinib for Localized Breast Cancer Therapy.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBreast cancer is the second most diagnosed and the fourth leading cause of death among affected women. Here, we have formulated erlotinib (ETB) ionogel to enhance the solubility and transdermal permeation of ETB post-topical application in breast cancer. The presence of the lymphatic network and mammary fat layers in the breast augments drug accumulation, thus evading the side effects of systemic chemotherapy and the invasive nature of current localized treatments.
methodsIonic liquid (IL) of choline geranate (CAGE) was synthesized via a salt metathesis reaction. ETB solubilized CAGE IL was subsequently transformed into an ionogel using Carbopol 980 NF and HPMC.
resultsThe HPMC ETB ionogel showed 71.04% permeation within 24 h and 64.3% drug release in 48 h following the Makoid-Banaker model. FTIR and SEM analysis confirmed the deeper dermal distribution of ionogel with the ability to maintain skin integrity. The ETB IL achieved the highest cytotoxicity in different breast cancer cell lines. The AUC, C
conclusionsThe improved in vivo efficacy and lower TEWL value depicted the non-toxic and permeable nature of ETB HPMC ionogel due to greater occlusivity, thus proving its transdermal yet localised effect in treating breast cancer.
Indexed as
Identifiers
42310188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.